Single molecules, formulated properly

The one people reach for when they want skin and hair to visibly change. Research describes GHK-Cu as driving collagen synthesis and remodelling the matrix underneath skin — which is why users report firmer, clearer skin, faded marks, and thicker hair at the follicle. It is also widely used after injury, because the same remodelling work applies to tissue that is trying to rebuild.

Copper complexes need their own handling — a chelator that protects other peptides will strip the copper out of this one.

Format

Lyophilised vial · reconstitute to 3 mL

Typical dose

1-2mg 1x/day subQ

pH

6.5

Osmolality

~198 mOsm/kg

Tonicity

Hypotonic

Sealed under

Argon

The one people use when something will not heal. Research describes BPC-157 as pro-angiogenic — growing new capillaries into tissue that needs them — with published work on gut lining, tendon, ligament and nerve. Users typically reach for it for stubborn joint and tendon problems, or gut issues that have not responded to anything else. It is systemic, so an injection anywhere is described as acting everywhere.

A small number of reports describe emotional blunting in some users; we note it rather than omit it.

Format

Lyophilised vial · reconstitute to 3 mL

Typical dose

250-500mcg 2x/day

pH

6.0

Osmolality

~162 mOsm/kg

Tonicity

Hypotonic

Sealed under

Argon

Usually run alongside BPC-157, because research describes them as doing different halves of the same job: BPC signals the rebuilding, this fragment handles getting cells to the site and closing the wound. People use it for recovery speed — soft tissue, flexibility, and injuries that keep re-aggravating.

The value option — the fragment carries the bulk of the repair activity at a fraction of the cost. Full-length TB-4 is listed separately.

Format

Lyophilised vial · reconstitute to 3 mL

Typical dose

2.5mg 2x/week

pH

6.0

Osmolality

~164 mOsm/kg

Tonicity

Hypotonic

Sealed under

Argon

The whole molecule rather than its active site — and the difference is real. TB-500 is a 7-amino-acid fragment chosen for cost and injection volume; full-length TB-4 is the entire 43-amino-acid protein the body actually makes. Research attributes additional activity to the parts the fragment leaves out: actin sequestration, immune modulation, and hair follicle stem cell activation on top of the cell migration and wound closure both share. It also clears more slowly, which is why it suits once-nightly dosing where the fragment suits daily. People choose it when they want the complete molecule and are willing to pay for it — it is the more expensive of the two by a wide margin.

The fragment is the value option and covers most of the repair use case. This is the completist choice.

Format

Lyophilised vial · reconstitute to 3 mL

Typical dose

Commonly run nightly; also formulated into SuperHEAL

pH

6.0

Osmolality

~161 mOsm/kg

Tonicity

Hypotonic

Sealed under

Argon

The quiet one people add when inflammation is the actual problem. Research describes KPV as damping inflammatory signalling inside immune cells, with published work on gut and skin inflammation. Users reach for it for IBD-type gut trouble and inflammatory skin conditions. Notably, the literature describes it as modulating inflammatory tone rather than suppressing immunity — so it is not trading one problem for another.

Format

Lyophilised vial · reconstitute to 3 mL

Typical dose

500mcg 1x/day subQ, or 500mcg-1mg oral

pH

6.0

Osmolality

~170 mOsm/kg

Tonicity

Hypotonic

Sealed under

Argon

The standard four-peptide healing blend — not something we invented, and we are not going to pretend otherwise. It became the default because the four components do genuinely different jobs: a copper tripeptide research describes as driving collagen synthesis and matrix remodelling, a gastric-derived peptide described as pro-angiogenic and active on gut, tendon and neural tissue, the active fragment of a thymic protein handling cell migration and wound closure, and an alpha-MSH tripeptide that damps inflammatory signalling without blunting immune surveillance. Rebuild, relocate, close, and keep inflammation from working against all three. People run it for recovery generally rather than for one injury — it is the maintenance version of the repair stack. What differs here is the formulation and the container, not the idea.

Copper-containing, so it needs its own vehicle — a chelator that protects other peptides strips the copper that constitutes the active molecule here. It cannot share a vial with anything for the same reason.

Format

Lyophilised vial · ~10 daily doses · reconstitute to 3 mL

Typical dose

5 mg GHK-Cu + 1 mg each BPC-157 / TB-500 / KPV daily

pH

6.5

Osmolality

~360 mOsm/kg

Tonicity

Mildly hypertonic

Sealed under

Argon

The one people use for visceral fat and sleep. Approved as Egrifta for HIV-associated lipodystrophy, and research describes it as prompting your own pituitary to release growth hormone in its natural pulsing pattern rather than replacing it. Users report deeper sleep, better body composition — particularly around the midsection — and firmer skin. Its cognitive trial data came from a majority-female cohort, which is unusual and worth knowing.

We also run an alternative cyclodextrin formulation mirroring the commercial product.

Format

Lyophilised vial · reconstitute to 3 mL

Typical dose

2 mg once daily

pH

6.0

Osmolality

~169 mOsm/kg

Tonicity

Hypotonic

Sealed under

Argon

The clean one. Research describes ipamorelin as triggering GH release without the cortisol, prolactin or hunger spikes reported for older secretagogues — that selectivity is exactly why people choose it. Commonly run with a GHRH analogue because they act on different receptors, and users report better sleep and recovery without the side effects that put them off other options.

Format

Lyophilised vial · reconstitute to 3 mL

Typical dose

100 mcg per injection, 2x/day

pH

6.0

Osmolality

~165 mOsm/kg

Tonicity

Hypotonic

Sealed under

Argon

Chosen specifically for the short action profile. Research describes the no-DAC form as producing GH pulses closer to the body's own rhythm than long-acting versions, which is why people who care about preserving natural pulsatility pick this one over the DAC variant. Usually paired with a ghrelin-receptor agonist.

Format

Lyophilised vial · reconstitute to 3 mL

Typical dose

100 mcg per injection, 2x/day

pH

6.0

Osmolality

~161 mOsm/kg

Tonicity

Hypotonic

Sealed under

Argon

The mitochondrial one on paper, and the first of its kind approved anywhere — cleared in September 2025 as Forzinity for Barth syndrome. Research describes it as binding cardiolipin in the inner mitochondrial membrane, stabilising the machinery that makes ATP and cutting reactive oxygen production. The mechanism is genuinely validated. What we will say plainly is that it failed prominently in trials for mitochondrial myopathy, dry AMD and heart failure, and that reported day-to-day effects are subtler than the mechanism would lead you to expect.

We publish the negative trial results because leaving them out would misrepresent the evidence.

Format

Lyophilised vial · reconstitute to 3 mL

Typical dose

20mg/day SC

pH

5.3–5.5

Osmolality

~224 mOsm/kg

Tonicity

Hypotonic

Sealed under

Argon

The metabolic one. Research describes MOTS-c as activating AMPK — the switch cells flip when they need to burn rather than store — with published work on insulin sensitivity, and an ovariectomised model reported it preventing both weight gain and insulin resistance, which is why it appears in the female-optimised formulations. Worth knowing that the felt effect is subtle; this is a compound people run for what the metabolic data describes rather than for anything dramatic day to day.

Highly cationic — needs a different vehicle approach from anionic peptides.

Format

Lyophilised vial · reconstitute to 3 mL

Typical dose

5mg 3x/week SC

pH

6.0

Osmolality

~161 mOsm/kg

Tonicity

Hypotonic

Sealed under

Argon

The wakefulness one, and the effect people describe is not stimulation — it is the absence of falling asleep. Users report that without it they fight drowsiness on long drives and after meals, and with it they simply do not. It is also the compound most often credited with breaking through a stall: research describes it as blocking NNMT, an enzyme reported to be upregulated two to three-fold in obesity, which otherwise burns through NAD+ precursors and methyl groups to make a metabolic dead-end. Blocking it is described as restoring those pools and improving fat oxidation, which is the mechanistic account of why progress restarts. Not approved for any indication and human data is early — we would rather say that than imply otherwise.

Format

Lyophilised vial · reconstitute to 3 mL

Typical dose

50mg/day oral

pH

5.0

Osmolality

~370 mOsm/kg

Tonicity

Hypertonic

Sealed under

Argon

The NAD+ one — and the reason we inject the precursor rather than NAD+ itself. Research describes the NAD+ molecule as too large and too charged to cross the cell membrane intact, so injected NAD+ does not enter cells as NAD+. It is cleaved outside the cell largely back down to NMN, and that NMN is what gets transported in and rebuilt into NAD+ by NMNAT. Injecting NAD+ is therefore a slower, costlier way of delivering NMN — every molecule has to be dismantled and reassembled first. NMN skips the round trip entirely: it is already the form the transporter accepts and one enzymatic step from NAD+. Subcutaneous delivery also avoids the gut degradation and first-pass metabolism the literature associates with poor oral absorption. Users report energy, recovery and sleep quality; published work links elevated NAD+ to sirtuin activity, mitochondrial function and DNA repair. Note the high solute load — any formulation at this concentration is necessarily hypertonic, which is why sting comes up with this one.

High API load makes any formulation at this concentration necessarily hypertonic.

Format

Lyophilised vial · reconstitute to 3 mL

pH

5.0

Osmolality

~849 mOsm/kg

Tonicity

Hypertonic

Sealed under

Argon

The telomere one — and it is on this list because of a result very few compounds can claim. Khavinson and colleagues (Bull Exp Biol Med, 2003) reported that Epitalon induced telomerase activity in human somatic cells and produced measurable telomere elongation, with telomere length assessed before and after exposure. Telomerase induction is not rare in the literature; actual elongation of human telomeres is, and that finding is why this peptide keeps its place in longevity protocols decades later. Alongside that, research describes it as normalising pineal melatonin rhythm — which is the effect users notice first and fastest: deeper, less fragmented sleep, often within days. Long-term Russian cohort work on the related pineal preparation reported reduced mortality over multi-year follow-up. Cycled rather than run continuously, because chronic dosing is described as potentially downregulating the very pathway it activates.

The landmark elongation data is in cultured human cells rather than a human in-vivo trial — we state that distinction rather than blur it. Cycled weekly on/off, not continuous.

Format

Lyophilised vial · reconstitute to 3 mL

pH

6.0

Osmolality

~168 mOsm/kg

Tonicity

Hypotonic

Sealed under

Argon

The senolytic. Research describes it as disrupting the interaction that lets senescent 'zombie' cells survive, triggering their clearance while sparing healthy cells. People use it in short cycles for the ageing case rather than any day-to-day effect. Preclinical only — the protocols circulating for this compound are not derived from human trials, and we say so rather than let that pass.

Protocols circulating for this compound are not derived from human data. We say so.

Format

Lyophilised vial · reconstitute to 3 mL

pH

6.0

Osmolality

~170 mOsm/kg

Tonicity

Hypotonic

Sealed under

Argon

The immune one. Research describes Tα-1 as promoting T-cell maturation and increasing NK cell activity, and it is sold pharmaceutically as Zadaxin in some markets. Users reach for it when they catch everything going around, or want immune support through winter — the literature describes the thymus shrinking with age, which is the rationale for supplementing it later in life. One of the highest-cost actives we carry, and a common target for underdosing elsewhere.

One of the highest-cost actives we carry — a common target for underdosing elsewhere.

Format

Lyophilised vial · reconstitute to 3 mL

Typical dose

1.6mg subQ 1x/day

pH

6.0

Osmolality

~161 mOsm/kg

Tonicity

Hypotonic

Sealed under

Argon

The desire one, and it works from the brain rather than the blood vessels — which is the distinction that matters to most people trying it. Approved as Vyleesi for hypoactive sexual desire disorder. Research describes MC4R activation in the brain as driving arousal in both sexes, so unlike PDE5 inhibitors it addresses wanting rather than only mechanics.

Format

Lyophilised vial · reconstitute to 3 mL

Typical dose

1.75mg SC

pH

6.0

Osmolality

~163 mOsm/kg

Tonicity

Hypotonic

Sealed under

Argon

The tanning one, without the sun. Approved in some markets as Scenesse for a photosensitivity disorder. Research describes it as stimulating eumelanin production through MC1R — so people use it for tanning with less UV exposure, and it is the more selective of the two Melanotans, which is why it carries fewer of the off-target effects.

Format

Lyophilised vial · reconstitute to 3 mL

pH

6.0

Osmolality

~162 mOsm/kg

Tonicity

Hypotonic

Sealed under

Argon

The one where you see the result in days rather than months. Users commonly report visible tanning within about three days, with far less sun exposure than would otherwise be needed — research describes it as driving eumelanin production through the melanocortin system. Because it is non-selective across melanocortin receptors rather than pigment-only, the literature also reports effects on libido and appetite, and users frequently rate that second effect as highly as the tanning. That same non-selectivity is the trade: the side-effect profile differs from Melanotan-1, and it is not approved anywhere. People choose it knowing that.

Non-selective activity is the reason its side-effect profile differs from Melanotan-1.

Format

Lyophilised vial · reconstitute to 3 mL

pH

6.0

Osmolality

~163 mOsm/kg

Tonicity

Hypotonic

Sealed under

Argon